Protection studies conducted using RTS,S as well as other available data, suggest that a robust antibody response coupled to a vigorous PfCSP epitope specific CD8+ T-cell response will likely be needed for a highly effective pre-erythrocytic stage malaria vaccine [2]–[4]. This evidence concerns the gene CD8A and malaria.